Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Phase 1

Withdrawn

Conditions: Central Nervous System Germ Cell Tumor
Malignant Glioma
Primitive Neuroectodermal Tumor
Recurrent Medulloblastoma
Anaplastic Ependymoma
Atypical Teratoid/Rhabdoid Tumor
Intracranial Myeloid Sarcoma
Recurrent Anaplastic Ependymoma
Recurrent Primitive Neuroectodermal Tumor
Choroid Plexus Carcinoma

Interventions: Drug: Etoposide
Drug: Fludarabine Phosphate
Procedure: Hematopoietic Cell Transplantation
Biological: Lapine T-Lymphocyte Immune Globulin
Drug: Melphalan
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Drug: Thiotepa

First Posted Date: 2020-08-21

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04521946

CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children

Phase 1

Recruiting

Conditions: Malignant Brain Neoplasm
Refractory Malignant Brain Neoplasm
Recurrent Malignant Brain Neoplasm

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes

First Posted Date: 2020-08-12

Last Posted Date: 2024-10-09

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 18

Registration Number: NCT04510051

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Haplo Peripheral Blood Sct In GVHD Prevention

Phase 1

Active, not recruiting

Conditions: GVHD
AML
ALL
MDS
MPN
CMML
Hodgkin Lymphoma
Non Hodgkin Lymphoma
Blood Stem Cell Transplant Failure
Graft Vs Host Disease

Interventions: Drug: FLUDARABINE
Drug: CYCLOPHOSPHAMIDE
Radiation: TBI
Drug: Melphalan
Drug: Sirolimus
Drug: Mycophenolate mofetil
Drug: RGI-2001

First Posted Date: 2020-07-16

Last Posted Date: 2024-03-07

Lead Sponsor: Zachariah Michael DeFilipp

Target Recruit Count: 25

Registration Number: NCT04473911

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Phase 2

Completed

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions: Biological: Anakinra
Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2020-06-16

Last Posted Date: 2024-05-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT04432506

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia, Adult
AML
AML, Adult

Interventions: Drug: Fludarabine
Drug: Vyxeos

First Posted Date: 2020-06-11

Last Posted Date: 2022-09-22

Lead Sponsor: University of California, San Diego

Target Recruit Count: 2

Registration Number: NCT04425655

Locations: 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Phase 1

Recruiting

Conditions: Cancer, Gastrointestinal
Gall Bladder Cancer
Stomach Cancer
Gastrointestinal Epithelial Cancer
Gastrointestinal Neoplasms
Cancer of Gastrointestinal Tract
Gastrointestinal Cancer
Pancreatic Cancer
Colo-rectal Cancer
Colon Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Tumor-Infiltrating Lymphocytes (TIL)
Drug: Aldesleukin

First Posted Date: 2020-06-11

Last Posted Date: 2023-03-03

Lead Sponsor: Intima Bioscience, Inc.

Target Recruit Count: 20

Registration Number: NCT04426669

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Phase 1

Recruiting

Conditions: Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

Interventions: Genetic: ALLO-501A
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-06-04

Last Posted Date: 2024-06-06

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 160

Registration Number: NCT04416984

Locations: 🇺🇸
Northside Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

and more 36 locations

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Phase 2

Active, not recruiting

Conditions: Hematologic Malignancy
Bone Marrow Transplant

Interventions: Drug: Tocilizumab
Drug: Fludarabine
Drug: Melphalan
Drug: Anti-thymocyte globulin (rabbit)
Radiation: Total Body Irradiation

First Posted Date: 2020-05-20

Last Posted Date: 2024-08-19

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 21

Registration Number: NCT04395222

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)

Phase 1

Withdrawn

Conditions: Ovarian Cancer Metastatic

Interventions: Drug: cyclophosphamide
Drug: fludarabine
Drug: IL-2 (Proleukin)
Genetic: Gene modified Tumour Infiltrating Lymphocytes (CoTIL-01)
Genetic: Unmodified Tumour Infiltrating Lymphocytes (UTIL-01)

First Posted Date: 2020-05-15

Last Posted Date: 2020-12-16

Lead Sponsor: Immetacyte Ltd

Registration Number: NCT04389229

Locations: 🇬🇧
The Christies Hospital, Manchester, United Kingdom
🇬🇧
Queens Elizabeth Hospital, Birmingham, United Kingdom

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

Phase 2

Recruiting

Conditions: Secondary Myelofibrosis
Primary Myelofibrosis

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Melphalan
Drug: Methotrexate
Drug: Mycophenolate Mofetil
Drug: Ruxolitinib
Drug: Tacrolimus
Radiation: Total-Body Irradiation
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Magnetic Resonance Imaging
Procedure: Ultrasound Imaging

First Posted Date: 2020-05-12

Last Posted Date: 2024-10-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 45

Registration Number: NCT04384692

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy